Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
538
total citations
- FWCI
- 42.56
- Percentile
- 100%
- References
- 37
Citations per year
Authors
24Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Response Evaluation Criteria in Solid Tumors
- Internal medicine
- Cohort
- Interim analysis
- Clinical endpoint
- Brain metastasis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of DefenseAwards: X81XWH-15-1-0203, W81XWH-16-1-0160
- MMerck
- MRMelanoma Research AllianceAward: 308721
- YCYale Cancer Center
- NINational Institutes of HealthAwards: R01 CA204002, P50CA196530, P50 CA121974, R01 CA158167, K24CA172123
- SUStand Up To CancerAwards: SU2C-AACR-DT17-15, SU2C-AACR-DT22-17